Deutsche Bank
OVID icon

Deutsche Bank’s Ovid Therapeutics OVID Stock Holding History

Deutsche Bank’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$402K Buy
+149,391
New +$385K ﹤0.01% 2892
2025
Q2 		– Sell
-105,177
Closed -$32.6K – 3698
2025
Q1 		$32.6K Hold
105,177
– – ﹤0.01% 3438
2024
Q4 		$97.8K Hold
105,177
– – ﹤0.01% 3288
2024
Q3 		$124K Hold
105,177
– – ﹤0.01% 3145
2024
Q2 		$81K Buy
105,177
+81,196
+339% +$226K ﹤0.01% 3181
2024
Q1 		$73.1K Buy
23,981
+1,097
+5% +$3.67K ﹤0.01% 3285
2023
Q4 		$73.7K Sell
22,884
-1,136
-5% -$3.88K ﹤0.01% 3346
2023
Q3 		$92.2K Buy
+24,020
New +$86.3K ﹤0.01% 3194
2021
Q3 		– Sell
-85,566
Closed -$335K – 4599
2021
Q2 		$335K Buy
85,566
+53,514
+167% +$211K ﹤0.01% 3478
2021
Q1 		$128K Sell
32,052
-440
-1% -$1.46K ﹤0.01% 3847
2020
Q4 		$75K Buy
32,492
+6,074
+23% +$28.3K ﹤0.01% 3993
2020
Q3 		$152K Buy
26,418
+4,633
+21% +$31K ﹤0.01% 3354
2020
Q2 		$160K Buy
+21,785
New +$102K ﹤0.01% 3235
2020
Q1 		– Sell
-23,165
Closed -$96K – 4681
2019
Q4 		$96K Buy
23,165
+12,896
+126% +$40.7K ﹤0.01% 3600
2019
Q3 		$33K Buy
10,269
+6,938
+208% +$15.8K ﹤0.01% 4122
2019
Q2 		$6K Sell
3,331
-253,931
-99% -$453K ﹤0.01% 5070
2019
Q1 		$454K Buy
257,262
+205,230
+394% +$513K ﹤0.01% 3511
2018
Q4 		$125K Sell
52,032
-196,420
-79% -$896K ﹤0.01% 4115
2018
Q3 		$1.41M Sell
248,452
-56,771
-19% -$430K ﹤0.01% 3083
2018
Q2 		$2.38M Buy
305,223
+9,501
+3% +$81.6K ﹤0.01% 2838
2018
Q1 		$2.09M Buy
295,722
+84,621
+40% +$685K ﹤0.01% 2830
2017
Q4 		$2.08M Buy
211,101
+6,607
+3% +$60.7K ﹤0.01% 2692
2017
Q3 		$1.75M Sell
204,494
-1,332
-0.6% -$11.1K ﹤0.01% 2629
2017
Q2 		$2.16M Buy
+205,826
New +$2.69M ﹤0.01% 2511

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Deutsche Bank's OVID Position: Q2 2026 in Review

Deutsche Bank opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 149,391 shares worth $402K. The stake represents ﹤0.01% of the portfolio and ranks #2892 among its holdings. This is a return to the name: Deutsche Bank previously reported a position in OVID as recently as Q1 2025.

Deutsche Bank first reported a position in OVID in Q2 2017 and has held it in 24 quarters since. The position peaked at $2.38M in Q2 2018. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Deutsche Bank held 149,391 shares of Ovid Therapeutics worth $402K as of Q2 2026.
  • Ovid Therapeutics was a new Deutsche Bank position in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #2892 holding.
  • Deutsche Bank first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 24 quarters since.
  • Deutsche Bank's Ovid Therapeutics position peaked at $2.38M in Q2 2018.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.